MARKET

ARAV

ARAV

Aravive Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.52
0.00
0.00%
Opening 14:39 03/05 EST
OPEN
6.64
PREV CLOSE
6.52
HIGH
6.70
LOW
6.01
VOLUME
177.83K
TURNOVER
--
52 WEEK HIGH
14.94
52 WEEK LOW
3.340
MARKET CAP
123.63M
P/E (TTM)
-3.1869
1D
5D
1M
3M
1Y
5Y
Aravive to Participate in Upcoming Virtual Investor Conferences in March
HOUSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual i...
GlobeNewswire · 3d ago
Insider Trends: Aravive Insider Receives Stock Award, Trend of Buys Extended
MT Newswires · 02/17 18:50
DJ Aravive Shares Rise 14% After Direct Offering Prices
Dow Jones · 02/16 15:49
BRIEF-Aravive Announces $21 Million Registered Direct Offering With Eshelman Ventures Priced At-The-Market
reuters.com · 02/16 12:35
Aravive Announces $21M Registered Direct Offering Of 2.875M Shares At $7.29/Share
Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV), a clinical-stage oncology company
Benzinga · 02/16 12:16
Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a securities purchase agreement with Eshelman Ventures, LLC to sell ...
GlobeNewswire · 02/16 12:00
What Percentage Of Aravive, Inc. (NASDAQ:ARAV) Shares Do Insiders Own?
A look at the shareholders of Aravive, Inc. ( NASDAQ:ARAV ) can tell us which group is most powerful. Large companies...
Simply Wall St. · 02/15 04:23
Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference
HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at the H.C. Wainwright Virtual BioConnect Conference taking place Ja...
GlobeNewswire · 01/04 21:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARAV. Analyze the recent business situations of Aravive Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARAV stock price target is 21.33 with a high estimate of 26.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 102
Institutional Holdings: 9.36M
% Owned: 49.36%
Shares Outstanding: 18.96M
TypeInstitutionsShares
Increased
17
154.87K
New
16
-127.94K
Decreased
15
453.81K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+1.03%
Key Executives
Chairman/Independent Director
Fredric Eshelman
Chairman/Independent Director
fredric Eshelman
President/Chief Executive Officer/Director
Gail McIntyre
Chief Financial Officer
Vinay Shah
Other
Reshma Rangwala
Director
Michael Rogers
Independent Director
Amato Giaccia
Independent Director
Eric Zhang
No Data
  • All
  • Financials
  • Insiders
More
About ARAV
Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.

Webull offers kinds of Aravive Inc stock information, including NASDAQ:ARAV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARAV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARAV stock methods without spending real money on the virtual paper trading platform.